Morepen Board proposed dividend after 23 years

Scores highest PAT of Rs. 118 crore in FY25

Lupin launches Eslicarbazepine Acetate tablets in US

Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity

Sigachi Industries receives CEP for Metformin Hydrochloride from EDQM

The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets

Ichnos Glenmark Innovation receives USFDA fast track designation for ISB 2001 for relapsed/refractory multiple myeloma

IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma

SMS Pharmaceuticals’ Vizag plant receives WHO Geneva prequalification

This significant milestone enhances our global regulatory standing

CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings

Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings

Aster DM Healthcare completes acquisition of 5% stake in Quality Care India

The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow

Medanta to set up a 400-bed super specialty hospital in Guwahati

The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital

Vimta Labs to invest Rs. 50 crores to Biologics CDMO business foray

The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides

Morepen to launch new fatty lever drug ‘Resmetirom’